Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/103067
Title: | Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes |
Author: | Sued, Omar Ambrosioni, Juan Nicolás, David Manzardo, Christian Agüero Santangelo, Fernando Claramonte, Xavier Plana Prades, Montserrat Tuset Creus, Montserrat Pumarola Suñé, Tomàs Gallart, Teresa Gatell, José M. Miró Meda, José M. |
Keywords: | Antiretrovirals Infeccions per VIH VIH (Virus) Resposta immunitària Inflamació Antiretroviral agents HIV infections HIV (Viruses) Immune response Inflammation |
Issue Date: | 17-Jul-2015 |
Publisher: | Public Library of Science (PLoS) |
Abstract: | BACKGROUND: Interventions during primary HIV infection (PHI) can modify the clinical course during the chronic phase. The long-term effect of structured treatment interruptions (STI) followed by low doses of interleukin-2 (IL-2) in treated PHI patients is unknown. METHODS: Twelve PHI patients with viral load (VL) <20 copies/mL, CD4 cells >500 cells/mm3, and CD4/CD8 ratio >1, on antiretroviral therapy (ART) initiated within the first 90 days of infection and continued for at least 12 months were included. They underwent four STI and were then allocated (week 0 of the study) to ART alone or ART plus low doses of IL-2. ART was stopped once VL <20 copies/mL ('final stop'). Primary endpoints were VL<3000 copies/mL and CD4 cells >500 cells/mm3 at 48 weeks; secondary endpoints were immune activation, inflammatory markers until 48 weeks and the time before resuming ART (CD4 <350 cells/mm3 or AIDS) after 'final stop', compared between groups. RESULTS: Ten out of 12 patients were males, median age was 35 years and the main risk was men-who-have-sex-with-men. Only one out of 12 patients (in the STI group) maintained VL<3000 copies/mL and CD4 cells >500 cells/mm3 without ART at 48 weeks. All other virological and immunological parameters were comparable between groups at week 0, 'final stop' and week 48. However, the proportion of CD8-CD38+ cells, tumor necrosis factor and srIL-2 were higher in the IL-2 group at 'final stop' and week 24. All these differences vanished during follow-up. At 5 years after the final stop 3 out of 6 patients in the IL-2 group and 6 out of 6 patients in the STI group have resumed ART (P = 0.19). CONCLUSIONS: STI and IL-2 failed to achieve virological control after ART interruption. STI were not deleterious in long-term follow-up, an important issue for eradication and functional cure trials. |
Note: | Reproducció del document publicat a: http://dx.doi.org/10.1371/journal.pone.0131651 |
It is part of: | PLoS One, 2015, vol. 10, num. 7, p. e0131651 |
URI: | http://hdl.handle.net/2445/103067 |
Related resource: | http://dx.doi.org/10.1371/journal.pone.0131651 |
ISSN: | 1932-6203 |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
660769.pdf | 757.37 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License